New cell cocktail aims to prevent transplant complications in kids with leukemia
NCT ID NCT07366801
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new method to prevent graft-versus-host disease (GVHD) in children and young adults with high-risk blood cancers who need a stem cell transplant from a half-matched donor. The approach combines specially enriched donor immune cells with a stem cell graft that has most T cells removed, along with reduced use of immune-suppressing drugs. The goal is to lower the risk of severe GVHD while keeping the immune system strong enough to fight infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Donor lymphocytes enriched with regulatory T cells, combined with a stem cell graft that has had most T cells removed
- What this could lead to
- If successful, this approach could reduce the risk of severe graft-versus-host disease while preserving the immune system's ability to fight infections after a stem cell transplant.
- What could go wrong
- This is an early pilot study with only 64 participants, so results may not apply to all patients. There is still a risk of graft-versus-host disease or serious infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, HIGH RISK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov, Moscow, 117198
RECRUITINGMoscow, Russia